2023
Gene-Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia.
Zhong C, Li S, Arroyo K, Morimoto L, de Smith A, Metayer C, Ma X, Kogan S, Gauderman W, Wiemels J. Gene-Environment Analyses Reveal Novel Genetic Candidates with Prenatal Tobacco Exposure in Relation to Risk for Childhood Acute Lymphoblastic Leukemia. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1707-1715. PMID: 37773025, DOI: 10.1158/1055-9965.epi-23-0258.Peer-Reviewed Original ResearchConceptsMaternal tobacco exposureAcute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaTobacco exposureLymphoblastic leukemiaLarge population-based studyPopulation-based studyEffects of tobaccoPrenatal tobacco exposureAryl hydrocarbon receptor repressor geneMode of deliverySelf-reported smokingIndividual-level risk factorsGenetic variantsPolygenetic risk scoresYear of birthAHRR hypomethylationSubsequent childhoodMaternal exposureGestational ageRisk factorsTobacco smokeRisk scoreBiological markersBlood spotsPer- and polyfluoroalkyl substances (PFAS) and thyroid hormone measurements in dried blood spots and neonatal characteristics: a pilot study
Rosen Vollmar A, Lin E, Nason S, Santiago K, Johnson C, Ma X, Godri Pollitt K, Deziel N. Per- and polyfluoroalkyl substances (PFAS) and thyroid hormone measurements in dried blood spots and neonatal characteristics: a pilot study. Journal Of Exposure Science & Environmental Epidemiology 2023, 33: 737-747. PMID: 37730931, PMCID: PMC10541328, DOI: 10.1038/s41370-023-00603-4.Peer-Reviewed Original ResearchConceptsThyroid hormone concentrationsNeonatal characteristicsThyroid hormone measurementsHormone concentrationsThyroid hormonesBlood spotsPilot studyNewborn DBSHormone measurementsPopulation-based studyThyroid hormone levelsEnvironmental risk factorsPFAS concentrationsNewborn screening testNon-parametric WilcoxonThyroid diseaseRisk factorsHormone levelsKruskal-Wallis testPFAS exposureThyroid hormone dataScreening testNeonatal DBSEnvironmental exposuresPerformance liquid chromatography-mass spectrometryBirth characteristics and risk of Ewing sarcoma
Wiemels J, Wang R, Feng Q, Yee A, Morimoto L, Metayer C, Ma X. Birth characteristics and risk of Ewing sarcoma. Cancer Causes & Control 2023, 34: 837-843. PMID: 37335392, PMCID: PMC10460323, DOI: 10.1007/s10552-023-01737-4.Peer-Reviewed Original ResearchConceptsBirth characteristicsEwing's sarcomaConclusionsThis population-based studyDisease riskMultivariable logistic regression modelNon-Hispanic white subjectsPopulation-based seriesPopulation-based studySignificant risk factorsMetastatic Ewing sarcomaEwing's sarcoma casesMinimal selection biasLogistic regression modelsYear of birthPurposeThe incidenceFetal growthRisk factorsSarcoma casesLower riskSarcomaMultiethnic populationBirth recordsWhite subjectsGenetic susceptibilityPredisposition allelesAssociation between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015
Cote D, Wang R, Morimoto L, Metayer C, Zada G, Wiemels J, Ma X. Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015. Cancer Causes & Control 2023, 34: 757-768. PMID: 37225897, PMCID: PMC10363066, DOI: 10.1007/s10552-023-01718-7.Peer-Reviewed Original ResearchConceptsOlder maternal ageMultivariable logistic regressionNon-Hispanic white individualsHigher maternal educationPituitary adenomasBirth characteristicsMaternal educationSignificant associationMaternal ageOdds ratioNon-Hispanic white raceUnconditional multivariable logistic regressionLogistic regressionParental sociodemographic characteristicsRegistry-based studyPopulation-based studyWhite individualsAdjusted odds ratioEarly-onset cancersNon-Hispanic whitesBirth pluralityIncident casesBlack raceFemale sexHispanic ethnicity
2022
Birth characteristics and risk of meningioma in a population-based study in California
Cote D, Wang R, Morimoto L, Metayer C, Stempel J, Zada G, Ma X, Wiemels J. Birth characteristics and risk of meningioma in a population-based study in California. Neuro-Oncology Advances 2022, 4: vdac173. PMID: 36479059, PMCID: PMC9721385, DOI: 10.1093/noajnl/vdac173.Peer-Reviewed Original ResearchPopulation-based studyHigher birth orderBirth characteristicsFemale sexRace/ethnicityBlack raceOdds ratioHigh riskUnconditional multivariable logistic regression modelsMultivariable logistic regression modelLarge population-based studyAge-stratified analysisConfidence intervalsCancer registry dataRisk of meningiomaAge of diagnosisCalifornia birth recordsPopulation-based linkageBirth orderLogistic regression modelsYear of birthGestational ageMaternal ageRisk factorsHigher birthweight
2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemiaPatterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugs
2020
Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in California
Deziel N, Zhang Y, Wang R, Wiemels JL, Morimoto L, Clark CJ, Metayer C, Ma X. Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in California. Thyroid 2020, 31: 596-606. PMID: 32912083, PMCID: PMC8195873, DOI: 10.1089/thy.2020.0217.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge of OnsetBirth CertificatesBirth OrderBirth WeightCaliforniaCase-Control StudiesChildChild, PreschoolEducational StatusFemaleHispanic or LatinoHumansIncidenceInfantInfant, NewbornMaleRace FactorsRegistriesRisk AssessmentRisk FactorsSex FactorsThyroid NeoplasmsTime FactorsYoung AdultConceptsPediatric thyroid cancerHigh birth weightFollicular thyroid cancerThyroid cancerHigher birth orderBirth characteristicsRisk factorsHispanic ethnicityBirth weightOdds ratioFirst primary thyroid cancerPapillary thyroid cancer casesBirth orderMultivariable logistic regression modelSecond primary malignanciesLong-term therapyAdjusted odds ratioPopulation-based studyPrimary thyroid cancerRecord linkage studyConfidence intervalsImportant risk factorCancer registry dataCase-control studyThyroid cancer casesClinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differencesGermline cancer predisposition variants and pediatric glioma: a population-based study in California
Muskens IS, de Smith AJ, Zhang C, Hansen HM, Morimoto L, Metayer C, Ma X, Walsh KM, Wiemels JL. Germline cancer predisposition variants and pediatric glioma: a population-based study in California. Neuro-Oncology 2020, 22: 864-874. PMID: 31970404, PMCID: PMC7283023, DOI: 10.1093/neuonc/noaa014.Peer-Reviewed Original ResearchConceptsCancer predisposition genesPathogenic germline variantsPathogenic variantsGermline variantsNeurofibromatosis 1Pediatric astrocytomasCandidate cancer predisposition genesPredisposition genesGene burden testingPediatric glioblastomaPediatric cancer predispositionMalignant pediatric brain tumorTertiary referral centerPopulation-based studyPediatric brain tumorsCancer predisposition variantsPediatric glioma patientsRare germline variantsTumor protein 53Whole-exome sequencingExome-wide levelReferral centerAstrocytoma patientsGlioma patientsBrain tumors
2019
The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia
Podoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 2019, 134: 2125. DOI: 10.1182/blood-2019-127563.Peer-Reviewed Original ResearchTherapeutic phlebotomyPopulation-based cohortPV patientsELN guidelinesET patientsPolycythemia veraEssential thrombocythemiaGuideline publicationCelgene CorporationCytoreductive therapyHU useMonthly proportionBoehringer IngelheimLarge population-based cohortAdvisory CommitteeDaiichi SankyoOlder adultsEuropean LeukemiaNet guidelinesEnd Results-MedicareProportion of patientsHealthcare Common Procedure Coding System codesPopulation-based studyPatterns of careTreatment of patientsPart D claimsClinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748. DOI: 10.1182/blood-2019-128821.Peer-Reviewed Original ResearchPopulation-based studyLR-MDSMedian overall survivalOverall survivalClinical effectivenessHypomethylating agentCelgene CorporationMedian durationRed blood cellsMedian timeRing sideroblastsBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoOlder adultsAbnormal erythroid precursorsTransfusion independence rateEnd Results-MedicareHigh-risk MDSErythropoiesis-stimulating agentsKaplan-Meier statisticsComparative clinical effectivenessEnd of studyPart D coverageIncidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea
Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea. Blood 2019, 134: 330. DOI: 10.1182/blood-2019-127568.Peer-Reviewed Original ResearchMyeloid hematological malignanciesHU usersPopulation-based studyHematological malignanciesCumulative incidenceCelgene CorporationMPN diagnosisCytoreductive therapySolid malignanciesGray's testPolycythemia veraMPN patientsEssential thrombocythemiaContinuous Part D coverageBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoImpact of hydroxyureaRetrospective cohort studyElixhauser comorbidity scorePV/ET myelofibrosisRisk regression modelsSAS version 9.4Part D coveragePhysician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.Peer-Reviewed Original ResearchConceptsRituximab discontinuationRituximab initiationHodgkin's lymphomaRelative riskPhysician experienceHigh-quality cancer careOlder adultsInitiation of rituximabEarly treatment discontinuationInfusion-related reactionsPopulation-based studySEER-Medicare dataNon-Hodgkin lymphomaModified Poisson regressionCancer treatment outcomesEarly discontinuationTreatment discontinuationAnticancer immunotherapyPhysician volumeCancer careImproved outcomesOncologists' experiencesTreatment outcomesDiscontinuationRituximab
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLOS ONE 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMyeloid neoplasmsCancer survivorsBreast cancerOlder womenOlder breast cancer survivorsTherapy-related myeloid neoplasmsCompeting-risks survival analysisAbsolute risk increaseBenefits of radiotherapyPopulation-based studyAbsence of chemotherapyRisk of developmentMultiple sensitivity analysesEligible patientsSubsequent chemotherapyAdjuvant radiotherapyLocalized diseaseCumulative incidenceInitial treatmentSEER registryPoor outcomeTreatment recommendationsMedicare claimsMN diagnosisParental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California
Wang R, Metayer C, Morimoto L, Wiemels JL, Yang J, DeWan AT, Kang A, Ma X. Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California. American Journal Of Epidemiology 2017, 186: 843-856. PMID: 28535175, PMCID: PMC5860074, DOI: 10.1093/aje/kwx160.Peer-Reviewed Original ResearchConceptsRecord linkage studyMaternal ageOdds ratioPediatric cancerParental agePopulation-based record linkage studyCentral nervous system tumorsRisk of lymphomaPopulation-based studyCancer registry dataNervous system tumorsRisk of leukemiaAge group 0Ages 0Pediatric cancer riskOlder paternal ageOlder age groupsTypes of cancerSystem tumorsRegistry dataCancer riskHigh riskGroup 0Birth recordsAge groupsHypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.Peer-Reviewed Original ResearchOverall survivalHR-MDSDiagnosis yearUS population-based analysisEnd Results-Medicare dataHigh-risk myelodysplastic syndromeLarge population-based studyConventional care regimensMedian overall survivalRetrospective cohort studyRisk myelodysplastic syndromesPopulation-based studyRecent registry dataPopulation-based analysisUse of decitabineAZA-001Unselected natureCohort studyConventional careExcess blastsOlder patientsTherapy usePatient selectionSurvival prolongationCare regimens
2010
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leukemia Research 2010, 35: 904-908. PMID: 21067809, PMCID: PMC3114277, DOI: 10.1016/j.leukres.2010.10.007.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromePatient characteristicsRefractory anemiaMultivariate logistic regression modelMultiple patient characteristicsPopulation-based studyUse of HMAsLogistic regression modelsElderly patientsExcess blastsMultilineage dysplasiaRefractory cytopeniaMDS patientsPatientsComorbiditiesAnemiaSyndromeHigher chanceRegression modelsHMAsAgentsIntroduction periodCytopeniasDysplasiaCancer
2009
Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States
Wang R, Gross CP, Halene S, Ma X. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes & Control 2009, 20: 1369-1376. PMID: 19455395, PMCID: PMC2921772, DOI: 10.1007/s10552-009-9362-7.Peer-Reviewed Original ResearchConceptsNeighborhood socioeconomic statusMyelodysplastic syndromeSocioeconomic statusElderly patientsHazard ratioMultivariate Cox proportional hazards modelCox proportional hazards modelSurvival of patientsPopulation-based studyRisk of deathRisk of mortalityProportional hazards modelImpact of SESLow socioeconomic statusCensus tractsPrognostic roleMDS patientsIndependent determinantsRefractory anemiaHistological subtypesHazards modelPatientsSES statusTractS scores